Stay updated on TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial
Sign up to get notified when there's something new on the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page.

Latest updates to the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.5.2 was added in the page footer, replacing Revision: v3.5.0.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded publication: Grimm MO et al., Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024;10(6):755-764. Removed Erratum for the same article (JAMA Oncol. 2024 Nov 1;10(11):1598).SummaryDifference0.0%

- Check31 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision: v3.4.3 added and Revision: v3.4.2 removed. This change does not alter core study information or user actions.SummaryDifference0.0%

- Check45 days agoChange DetectedA publication citation was added to the Publications section and then removed, resulting in no net change to the page content.SummaryDifference0.0%

- Check66 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior Notice about government funding lapse and Revision: v3.4.1.SummaryDifference0.3%

Stay in the know with updates to TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page.